Epic said 85% of its healthcare customers are now live on generative AI tools as it rolled out native ambient documentation and previewed a new AI-native interface called Ergo at its 2026 user conference.
A Cleveland Clinic study of 4,000 clinicians found 60% said an ambient AI scribe increased their likelihood of staying in practice, with 97% reporting overall satisfaction with the tool.
Wood Mackenzie projects utilities will build only about 28% of the 1,066 gigawatts requested for AI data centers, with the rest amounting to duplicative 'phantom load' that could distort grid planning.
Clair Health raised $11.6 million led by Khosla Ventures to build a wrist wearable that uses machine learning to infer estrogen, progesterone, LH and FSH levels without blood tests, launching in November.
A University of Toronto-led study finds that of 1,357 FDA-cleared AI medical devices, only three have ever been tested on whether they improve patient outcomes like survival or hospitalization.
Abridge is expanding from an ambient AI scribe into billing and clinical trial screening, backed by an Eli Lilly equity investment and a new NVIDIA-co-developed clinical foundation model.
A Nature Medicine study found OpenAI's ChatGPT Health under-triaged more than half of emergency-care cases and showed inverted suicide-risk alerts, testing the tool across 960 clinical interactions.
Labcorp will deploy PathAI's FDA-cleared AISight Dx digital pathology platform across its national lab network, extending a partnership that began with a 2019 strategic investment.
a2z Radiology AI's newly FDA-cleared tool flags seven acute conditions from a single abdomen-pelvis CT scan, and the startup says it cut radiologist reporting time by 17.8% in testing.
Artera's ArteraAI Breast, cleared by the FDA on May 6, 2026, generates a metastasis risk score directly from biopsy slides without requiring additional genomic tissue testing.